OsteoCool™ 2.0 Radiofrequency ablation system

The OsteoCool™ 2.0 system combines internally-cooled radiofrequency (RF) ablation probes with a 100W generator and simultaneous, four-probe capability to palliatively treat painful bone tumors.

About the therapy


Product details

The OsteoCool™ 2.0 RF ablation system helps you deliver optimal care for your patients – faster. OsteoCool™ 2.0 ablates up to 30% faster than OsteoCool™ 1.0,1,† supports the use of four probes simultaneously, and delivers a market-leading 20W of power per channel.2-4

Independent channel control allows you to start and stop ablation on each channel individually, while internally-cooled probes reduce the risk of charring without introducing ionic solutions into the ablation.

With the widest selection of probe sizes2-4 and OsteoMap™ technology, OsteoCool™ 2.0 provides consistent, predictable ablation zones with the flexibility to tailor the ablation zone to your patients' needs. Backed by OPuS One5,‡, the largest study of RF ablation in bone metastases, the OsteoCool™ 2.0 RF ablation system gives you the control to deliver powerful, predictable, and proven pain relief.

Image from breast cancer case study with Dr. Levy.

Image courtesy of Dr. Jason Levy

OsteoCool™ hard bone access kit

The Medtronic bone access toolkit includes a tapered cannula, sharper trocar, and enhanced drill design – a system that allows improved access to sclerotic bone. These tools are compatible with the existing OsteoCool™ RF ablation probes.

The tools:

- Offer faster access to sclerotic bone6†
- Reduce the force required to advance the tool6†
- Are versatile for use for all cases



  • Intended for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body
  • Coagulation and ablation of tissue in bone during surgical procedures including palliation of pain associated with metastatic lesions involving bone in patients who have failed or are not candidates for standard therapy
  • Ablation of benign bone tumors such as osteoid osteoma


  • As a consequence of electrosurgery, damage to surrounding tissue through iatrogenic injury could occur
  • Pulmonary embolism

Talk to a Medtronic representative to learn more about OsteoCool™ 2.0

* Indicates a required field.

† Bench testing may not be indicative of clinical results

‡ The original OsteoCool™ system was used in the OPuS One study


Based on internal data: ETR 30101200, OsteoCool 2.0 Lesion Validation Test Report, 20 samples. 2023.


Clarivate Interventional Oncology Devices Market Insights United States report, December 2022.


Stryker OptaBlate™ RF Generator System IFU 700001075365 Rev-AC.


Merit MetaSTAR™ RF Generator IFU 403321001_001.


OPuS One. Levy J, David E, Hopkins T, et al. Radiofrequency Ablation Provides Rapid and Durable Pain Relief for the Palliative Treatment of Lytic Bone Metastases Independent of Radiation Therapy: Final Results from the OsteoCool Tumor Ablation Post-Market Study. Cardiovasc Intervent Radiol. 2023;46(5):600-609.


Medtronic data on file: ETR 31101395, Repetitive Impact and Axial Compression Bench Testing, N=6 of each tool tested. January 2023.